References

  1. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32(Suppl):S125-127.
  2. Jankovic J. Parkinsonism-plus syndromes. Mov Disord 1989;4(Suppl 1): S95-S119.
  3. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann Neurol 1997;41:706-715.
  4. Pickering-Brown S, Baker M, Yen SH, et al. Pick's disease is associated with mutations in the tau gene. Ann Neurol 2000;48:859-867.
  5. Lanska DJ, Currier RD, Cohen M, et al. Familial progressive subcortical gliosis. Neurology 1994;44:1633-1643.
  6. Sumi SM, Bird TD, Nochlin D, Raskind MA. Familial presenile dementia with psychosis associated with cortical neurofibrillary tangles and degeneration of the amygdala. Neurology 1992;42:120-127.
  7. Wszolek ZK, Pfeiffer RF, Bhatt MH, et al. Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Ann Neurol 1992;32:312-320.
  8. Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR, Ghetti B. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci USA 1997;94: 4113-4118.
  9. Lynch T, Sano M, Marder KS, et al. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 1994;44:1878-1884.
  10. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-705.
  11. Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998;43:815-825.
  12. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998;95:7737-7741.
  13. Wszolek ZK, Tsuboi Y, Farrer M, Uitti RJ, Hutton ML. Hereditary tauopathies and parkinsonism. Adv Neurol 2003;91:153-163.
  14. Reed LA, Wszolek ZK, Hutton M. Phenotypic correlations in FTDP-17. Neurobiol Aging 2001;22:89-107.
  15. Tsuboi Y, Baker M, Hutton ML, et al. Clinical and genetic studies of families with the tau N279K mutation (FTDP-17). Neurology 2002;59:1791-1793.
  16. Ghetti B, Hutton M, Wszolek ZK. Frontotemporal dementia and parkinsonism linked to chromosome 17 associated with tau gene mutations (FTDP-17T). In: Dickson D, ed. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: International Society of Neuropathology Press, 2003:86-102.
  17. Basun H, Almkvist O, Axelman K, et al. Clinical characteristics of a chromosome 17-linked rapidly progressive familial frontotemporal dementia. Arch Neurol 1997;54:539-544.
  18. Lendon CL, Lynch T, Norton J, et al. Hereditary dysphasic disinhibition dementia: a frontotemporal dementia linked to 17q21-22. Neurology 1998;50:1546-1555.
  19. Heutink P, Stevens M, Rizzu P, et al. Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: a genetic and clinicopathological study of three Dutch families. Ann Neurol 1997;41:150-159.
  20. Rademakers R, Cruts M, Dermaut B, et al. Tau negative frontal lobe dementia at 17q21: significant finemapping of the candidate region to a 4.8 cM interval. Mol Psychiatry 2002;7:1064-1074.
  21. Froelich S, Basun H, Forsell C, et al. Mapping of a disease locus for familial rapidly progressive frontotemporal dementia to chromosome 17q12-21. Am J Med Genet 1997;74:380-385.
  22. Wszolek ZK, Tsuboi Y, Uitti RJ, Reed L. Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology 2000;55:1939.
  23. Tsuboi Y, Uitti RJ, Delisle MB, et al. Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family. Arch Neurol 2002;59:943-950.
  24. Harding AE. The clinical features and classification of the late onset autosomal dominant cerebellar ataxias: a study of 11 families, including descendants of "the Drew family of Walworth." Brain 1982;105:1-28.
  25. Schols L, Peters S, Szymanski S, et al. Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 2000;57: 1495-1500.
  26. Jardim LB, Pereira ML, Silveira I, Ferro A, Sequeiros J, Giugliani R. Neurologic findings in Machado-Joseph disease: relation with disease duration, subtypes, and (CAG)n. Arch Neurol 2001;58:899-904.
  27. Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 2000;55:800-805.
  28. Shan DE, Soong BW, Sun CM, Lee SJ, Liao KK, Liu RS. Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism. Ann Neurol 2001;50:812-815.
  29. Furtado S, Farrer M, Tsuboi Y, et al. SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. Neurology 2002;59:1625-1627.
  30. Lu CS, Wu Chou YH, Yen TC, Tsai CH, Chen RS, Chang HC. Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2. Mov Disord 2002;17:1046-1051.
  31. Gwinn-Hardy K, Singleton A, O'Suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling Parkinson disease in a black family. Arch Neurol 2001;58:296-299.
  32. Subramony SH, Hernandez D, Adam A, et al. Ethnic differences in the expression of neurodegenerative disease: Machado-Joseph disease in Africans and Caucasians. Mov Disord 2002;17:1068-1071.
  33. Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. In: Marsden CD, Fahn S, eds. Movement Disorders 2. London: Butterworths, 1987:332-358.
  34. Evidente VG, Advincula J, Esteban R, et al. Phenomenology of "Lubag" or X-linked dystonia-parkinsonism. Mov Disord 2002;17:1271-1277.
  35. Evidente VG, Gwinn-Hardy K, Hardy J, Hernandez D, Singleton A. X-linked dystonia ("Lubag") presenting predominantly with parkinsonism: a more benign phenotype? Mov Disord 2002;17:200-202.
  36. Evidente VGH, Dickson D, Singleton A, Natividad F, Hardy D. Novel neuropathological findings in Lubag or X-linked dystonia-parkinsonism (abstract). Mov Disord 2002;17(Suppl 5):S294.
  37. Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994;8:236-242.
  38. Tassin J, Durr A, Bonnet AM, et al. Levodopa-responsive dystonia: GTP cyclohydrolase I or parkin mutations? Brain 2000;123:1112-1121.
  39. Kramer PL, Mineta M, Klein C, et al. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. Ann Neurol 1999;46:176-182.
  40. Pittock SJ, Joyce C, O'Keane V, et al. Rapid-onset dystonia-parkinsonism: a clinical and genetic analysis of a new kindred. Neurology 2000;55:991-995.
  41. Grotzsch H, Pizzolato GP, Ghika J, et al. Neuropathology of a case of dopa-responsive dystonia associated with a new genetic locus, DYT14. Neurology 2002;58:1839-1842.
  42. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
  43. Rubinsztein DC, Leggo J, Chiano M, et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci USA 1997;94:3872-3876.
  44. Squitieri F, Berardelli A, Nargi E, et al. Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis. Clin Genet 2000;58:50-56.
  45. Louis ED, Anderson KE, Moskowitz C, Thorne DZ, Marder K. Dystonia-predominant adult-onset Huntington disease: association between motor phenotype and age of onset in adults. Arch Neurol 2000;57:1326-1330.
  46. de la Monte SM, Vonsattel JP, Richardson EP Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988;47:516-525.
  47. Campbell AMG, Corner BD, Norman RM, Urich H. The rigid form of Huntington's disease. J Neurol Neurosurg Psychiatry 1961;24:71-77.
  48. van Dijk JG, van der Velde EA, Roos RA, Bruyn GW. Juvenile Huntington disease. Hum Genet 1986;73:235-239.
  49. Bittenbender JB, Quadfasel FA. Rigid and akinetic forms of Huntington's chorea. Arch Neurol 1962;7:37-50.
  50. Roos RA, Vegter-van der Vlis M, Hermans J, et al. Age at onset in Huntington's disease: effect of line of inheritance and patient's sex. J Med Genet 1991;28:515-519.
  51. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry 1998;65:577-579.
  52. Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C, Chandhuri KR. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry 2000;68: 238-241.
  53. Thompson PD, Berardelli A, Rothwell JC, et al. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 1988;111:223-244.
  54. Garcia Ruiz PJ, Gomez Tortosa E, Sanchez Bernados V, Rojo A, Fontan A, Garcia de Yebenes J. Bradykinesia in Huntington's disease. Clin Neuropharmacol 2000;23:50-52.
  55. Perry TL, Bratty PJ, Hansen S, Kennedy J, Urquhart N, Dolman CL. Hereditary mental depression and Parkinsonism with taurine deficiency. Arch Neurol 1975;32:108-113.
  56. Perry TL, Wright JM, Berry K, Hansen S, Perry TL Jr. Dominantly inherited apathy, central hypoventilation, and Parkinson's syndrome: clinical, biochemical, and neuropathologic studies of 2 new cases. Neurology 1990;40:1882-1887.
  57. Purdy A, Hahn A, Barnett HJ, et al. Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. Ann Neurol 1979;6:523-531.
  58. Roy EP III, Riggs JE, Martin JD, Ringel RA, Gutmann L. Familial parkinsonism, apathy, weight loss, and central hypoventilation: successful long-term management. Neurology 1988;38:637-639.
  59. Lechevalier B, Schupp C, Fallet-Bianco C, et al. Familial parkinsonian syndrome with athymhormia and hypoventilation [French]. Rev Neurol (Paris) 1992;148:39-46.
  60. Bhatia KP, Daniel SE, Marsden CD. Familial parkinsonism with depression: a clinicopathological study. Ann Neurol 1993;34:842-847.
  61. Tsuboi Y, Wszolek ZK, Kusuhara T, Doh-ura K, Yamada T. Japanese family with parkinsonism, depression, weight loss, and central hypoventilation. Neurology 2002;58:1025-1030.
  62. Elibol B, Kobayashi T, Atac FB, et al. Familial parkinsonism with apathy, depression and central hypoventilation (Perry's syndrome). In: Mizuno Y, Fisher A, Hanin I, eds. Mapping the progress of Alzheimer's and Parkinson's disease. New York: Kluwer Academic/Plenum Publishers, 2002:285-290.
  63. Bowcock AM, Farrer LA, Hebert JM, et al. Eight closely linked loci place the Wilson disease locus within 13q14-q21. Am J Hum Genet 1988;43:664-674.
  64. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993;5:327-337.
  65. Tanzi RE, Petrukhin K, Chernove I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993;5:344-350.
  66. Gow PJ, Smallwood RA, Angus PW, Smith AL, Wall AJ, Sewell RB. Diagnosis of Wilson's disease: an experience over three decades. Gut 2000;46:415-419.
  67. Arima M, Takeshita K, Yoshino K, Kitahara T, Suzuki Y. Prognosis of Wilson's disease in childhood. Eur J Pediatr 1977;126:147-154.
  68. Menkes JH. Wilson disease. In: Pulst S-M, ed. Genetics of Movement Disorders. Amsterdam: Academic Press, 2003:341-352.
  69. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912;34:295-509.
  70. Lingam S, Wilson J, Nazer H, Mowat AP. Neurological abnormalities in Wilson's disease are reversible. Neuropediatrics 1987;18:11-12.
  71. Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden-Spatz syndrome. Arch Neurol 1974;30:70-83.
  72. Swaiman KF. Hallervorden-Spatz syndrome. Pediatr Neurol 2001;25:102-108.
  73. Jankovic J, Kirkpatrick JB, Blomquist KA, Langlais PJ, Bird ED. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology 1985;35:227-234.
  74. Alberca R, Rafel E, Chinchon I, Vadillo J, Navarro A. Late onset parkinsonian syndrome in Hallervorden-Spatz disease. J Neurol Neurosurg Psychiatry 1987;50:1665-1668.
  75. Taylor TD, Litt M, Kramer P, et al. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet 1996;14:479-481.
  76. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-349.
  77. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003;348:33-40.
  78. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-354.
  79. Gitlin JD. Aceruloplasminemia. Pediatr Res 1998;44:271-276.
  80. Hallervorden J, Spatz H. Eigenartige erkrankung im extrapyramidalen system mit besonderer beteiligung des globus pallidus und der substantia nigra. Z Gesamte Neurol Psychiatrie 1922:79:254-302.
  81. Wakabayashi K, Yoshimoto M, Fukushima T, et al. Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. Neuropathol Appl Neurobiol 1999;25:363-368.
  82. Wakabayashi K, Fukushima T, Koide R, et al. Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and Lewy body pathology. Acta Neuropathol (Berl) 2000;99:331-336.
  83. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Neurochemistry 1990;54:823-827.
  84. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996;40:663-671.
  85. Gu M, Cooper JM, Taanman JW, Schapira AH. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 1998;44:177-186.
  86. Swerdlow RH, Parks JK, Davis JN II, et al. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol 1998;44:873-881.
  87. Simon DK, Pulst SM, Sutton JP, Browne SE, Beal MF, Johns DR. Familial multisystem degeneration with parkin-sonism associated with the 11778 mitochondrial DNA mutation. Neurology 1999;53:1787-1793.
  88. Gasser T, Bressman S, Dürr A, Higgins J, Klockgether T, Myers RH. Molecular diagnosis of inherited movement disorders: Movement Disorders Society Task Force on Molecular Diagnosis. Mov Disord 2003;18:3-18.

Was this article helpful?

0 0

Post a comment